PURPOSE: The purpose of the study was to determine whether older patients with metastatic cancer continue to take medications for the treatment of pre-existing co-morbidities after the diagnosis of metastatic disease. METHODS: Between November 2008 and June 2009, patients over the age of 65 with metastatic cancer were interviewed. Medical records were reviewed in order to ascertain current medication use and relevant past medical history. Classes of medication of interest were prospectively defined; these were anti-hypertensives, lipid-lowering drugs, anti-platelet agents, anti-coagulants and bisphosphonates. RESULTS: One hundred patients were recruited, with a median age of 73.5 years (range 65-88); 52% were women. The primary cancer sites were breast, 36%; prostate, 27%; colon, 14%; other, 23%. The median performance status of the patients was 2. The median number of medications was 7 (range 1-17). Eighty-one percent of patients were found to be taking one or more of the predefined medications for treatment of a long-term co-morbidity. Overall 52% of patients had side effects attributed to these medications. CONCLUSIONS: Patients with metastatic cancer continue to take drugs for prevention of co-morbidities which are associated with side effects and inconvenience. The benefits of these drugs are likely to be minimal, and medication reviews should be undertaken to address their appropriateness.
PURPOSE: The purpose of the study was to determine whether older patients with metastatic cancer continue to take medications for the treatment of pre-existing co-morbidities after the diagnosis of metastatic disease. METHODS: Between November 2008 and June 2009, patients over the age of 65 with metastatic cancer were interviewed. Medical records were reviewed in order to ascertain current medication use and relevant past medical history. Classes of medication of interest were prospectively defined; these were anti-hypertensives, lipid-lowering drugs, anti-platelet agents, anti-coagulants and bisphosphonates. RESULTS: One hundred patients were recruited, with a median age of 73.5 years (range 65-88); 52% were women. The primary cancer sites were breast, 36%; prostate, 27%; colon, 14%; other, 23%. The median performance status of the patients was 2. The median number of medications was 7 (range 1-17). Eighty-one percent of patients were found to be taking one or more of the predefined medications for treatment of a long-term co-morbidity. Overall 52% of patients had side effects attributed to these medications. CONCLUSIONS:Patients with metastatic cancer continue to take drugs for prevention of co-morbidities which are associated with side effects and inconvenience. The benefits of these drugs are likely to be minimal, and medication reviews should be undertaken to address their appropriateness.
Authors: Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson Journal: N Engl J Med Date: 2002-01-10 Impact factor: 91.245
Authors: M Borner; D Koeberle; R Von Moos; P Saletti; D Rauch; V Hess; A Trojan; D Helbling; B Pestalozzi; C Caspar; T Ruhstaller; A Roth; A Kappeler; D Dietrich; D Lanz; W Mingrone Journal: Ann Oncol Date: 2008-03-17 Impact factor: 32.976
Authors: Hyman Muss; Javier Cortes; Linda T Vahdat; Fatima Cardoso; Chris Twelves; Jantien Wanders; Corina E Dutcus; Jay Yang; Seth Seegobin; Joyce O'Shaughnessy Journal: Oncologist Date: 2014-03-28
Authors: Joanne Reeve; Michelle Maden; Ruaraidh Hill; Amadea Turk; Kamal Mahtani; Geoff Wong; Dan Lasserson; Janet Krska; Dee Mangin; Richard Byng; Emma Wallace; Ed Ranson Journal: Health Technol Assess Date: 2022-07 Impact factor: 4.106
Authors: Justin P Turner; Kris M Jamsen; Sepehr Shakib; Nimit Singhal; Robert Prowse; J Simon Bell Journal: Support Care Cancer Date: 2015-10-09 Impact factor: 3.603
Authors: Matthew P Banegas; Marc A Emerson; Alyce S Adams; Ninah S Achacoso; Neetu Chawla; Stacey Alexeeff; Laurel A Habel Journal: J Cancer Surviv Date: 2018-10-18 Impact factor: 4.442